17th March 2017

Length of stay

Data from 7 UK NHS centres 1

This retrospective study investigated the impact of rifaximin-α for secondary prevention of OHE on hospital resource utilisation using real world data from 7 UK centres. 1
Mean annual hospital length of stay per patient

Adapted from Orr et al. 2016

  • Absolute reduction 12.9 days/person/year
  • Relative reduction 52.7%, p<0.001
Mean annual length of stay per patient reduced from 24.4 days before to 11.5 days during rifaximin-α treatment 1
 
  • Absolute reduction 4.9 days/admission
  • Relative reduction 36.3%, p=0.017
Mean hospital length of stay per admission decreased from 13.5 days/admission before to 8.6 days/admission during rifaximin-α treatment 1
Mean hospital length of stay per admission

Adapted from Orr et al. 2016


Data from the IMPRESS study 2,3

A retrospective, observational, multicentre study including 145 patients with HE from 11 UK NHS centres. Conducted from Aug 2014 to Jun 2015.
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
This study was sponsored by Norgine.
Total number of hospital bed days 2 All-cause admissions

Hospital bed days per patient 3 All-cause admissions
 

Safety
  • 4% patients (9/145) reported adverse drug reactions(ADRs)
  • 4/9 of these patients had C difficile infection and none discontinued treatment
  • No serious ADRs were reported

UK/XIF5/0719/0523  DOP: October 2019

References

  1. Orr J G, Currie C J et al. Liver Int 2016;36:1295-1303
  2. Hudson M, et al. Frontline Gastroenterology. Published Online First: 07-April-2017. doi:10.1136/flgastro-2016-100792
  3. Hudson M, et al. Frontline Gastroenterology. Published Online First: 07-April-2017. doi:10.1136/flgastro-2016-100792 Supplementary Material
Seven UK participating centres agreed a standardised data collection pro-forma. Patients with chronic liver disease who were treated with rifaximin-α for secondary prevention of overt hepatic encephalopathy (OHE) were included.* Details of all causes of HE and emergency hospital admissions were requested at 3, 6 and 12 months before and after rifaximin-α initiation. Clinical data were recorded at baseline, at 3, 6 and 12 months before and after rifaximin-α initiation.
87% of patients (n=282) were taking concomitant lactulose.
*Some patients included were on 3 x 400 mg daily as this was prior to the launch of the UK licensed dose of TARGAXAN® 550 mg twice a day.

A retrospective, observational, multicentre study including 145 patients from 11 UK NHS centres. Conducted from Aug 2014 to Jun 2015.
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
INCLUSION CRITERIA: Clinical diagnosis of HE. HE diagnosed prior to rifaximin-α initiation. Initiated on rifaximin-α at least 12 months prior data collection.
EXCLUSION CRITERIA: Rifaximin-α initiated at other hospitals. Medical records unavailable.

Details of hospitalisations and hospital visits were extracted from NHS Trust electronic databases. Analysis included only alive patients at the end of 6 and 12 month periods.
IMPRESS study was sponsored and funded by Norgine

Rifaximin-α initiation dose was 1100mg/day (licensed dose) in 30%, 1200 mg/day in 64%, and other doses in 6% of patients, respectively.
This study included patients started on rifaximin-a prior to the launch of TARGAXAN® 550mg bd. 82% of patients (n=119) were taking concomitant lactulose at baseline.